Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03280667
Title Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)
Acronym KEYPAD
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Age Groups: adult | senior
Covered Countries AUS

No variant requirements are available.